Regulatory & Reimbursement Newsletter

Biocom California submitted comments on an FDA draft guidance document, the federal government reopened, the FDA has a new director of its Center for Drug Evaluation and Research (CDER), and more.

Biocom California submitted its comment letter, the FDA announced the first nine recipients of the Commissioner’s National Priority Voucher, publicly released internal filing checklists, and more.